Navigation Links
RainDance Technologies Appoints Olex Vice President, System Development

LEXINGTON, Mass., Aug. 13 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the appointment of Michael B. Olex as Vice President, System Development, effective immediately.

"As RainDance introduces its exciting RainStorm(TM) droplet-based technology to market, Mr. Olex will play a key leadership role in designing, developing, and integrating complete systems for commercialization, including instrumentation, consumables, and reagents," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "He will immediately focus on our Sequence Enrichment application for targeted genomic sequencing that will be launched later this year. With his deep experience in life sciences management, Mr. Olex will establish productive, efficient product transfer procedures from engineering to manufacturing, including the development of manufacturing processes," McNary said.

Olex joins RainDance from BioTrove, where he was Vice President, Manufacturing, and established the company's OpenArray(TM) consumable and instrumentation manufacturing departments. He also served as Senior Vice President at U.S. Genomics; President of International Light; Director, Business Projects at Applied Biosystems; and Vice President of Manufacturing at PerSeptive Biosystems. Olex holds a master of business administration degree from Case Western Reserve University, a master of science degree in electrical engineering from Cleveland State University, and a bachelor's degree in electrical engineering from the University of Detroit.

About RainDance Technologies, Inc.

RainDance Technologies is a provider of innovative droplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company's technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance's initial application will focus on the targeted resequencing of the human genome -- one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Sir Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council's Laboratory of Molecular Biology in Cambridge.

For more information, please visit

SOURCE RainDance Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Technologies Appoints McNary President and CEO
2. RainDance Appoints Becker Chief Commercial Officer
3. RainDance Announces Company Relocation and Manufacturing Startup
4. RainDance Appoints Kelly Chief Operating Officer
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
9. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
10. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
11. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
Post Your Comments:
(Date:11/30/2015)... Israel , Nov. 30, 2015 ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... has been awarded an additional grant of approximately $735,000 from ... (OCS). This grant, the second this year, brings the total ... $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... , November 26, 2015 --> ... company specializing in imaging technologies, announced today that it has ... part of the Horizon 2020 European Union Framework Programme for ... large-scale clinical trial in breast cancer. , ... --> --> The study ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
Breaking Biology News(10 mins):